{"ticker": {"uuid": "02d230d0-066f-4cd9-843e-312ad1a517d6", "symbol": "APRE", "name": "Aprea Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxQOWRyOXFBVDdjdUw1aVZSX2VSckJGR1Jac2hiWXVFS2loVk1qUXhuN2ZaQ2ZUYmh1ZVlqTzZ5eGJoRS1jVDF6Z3BHbnotN0otZjhKV05IbFNqMW5VXy1VMjEyQ2tGWUVETlNNbTFQMWZPUV9jRHFBNEIxZTUzalFrS2tCSHVrZmt1bzJ6Q2lGRVVZdEVjeTFBRFhLbUtOUUdGQ3lERFRvRWlwbkhRRkxqMm5odjM5R2Q2NGlFTzFhUVN6U2l5SVlkOHV6WGl4dHJsbUlrN25XU1VUdkFnSk02S3dBdHlvRGlaQ2Q4V2hoU056VXJ3ZXpBbDV6WmI?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T23:28:21+00:00", "published_display": "14 Jul 2026 23:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to EBITDA forward of Aprea Therapeutics, Inc. \u2013 NASDAQ:APRE", "summary": "This article provides financial information for Aprea Therapeutics, Inc. (NASDAQ: APRE), specifically detailing its Enterprise Value to EBITDA forward. It lists various data providers for market and reference data, along with several copyright notices. The content appears to be a", "url": "https://www.tradingview.com/symbols/NASDAQ-APRE/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T11:39:18", "published_display": "06 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APRE - Aprea Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial snapshot of Aprea Therapeutics Inc (APRE), including its latest stock performance, key financial metrics, volatility, and various fundamental and technical indicators. It covers share statistics, profitability ratios, earnings per share,", "url": "https://finviz.com/stock?t=APRE&p=w&b=1&r=y2&ty=ocv&e=2026-04-20", "source_name": "Finviz", "published_at": "2026-07-04T10:41:07", "published_display": "04 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APRE Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Aprea Therapeutics, Inc. (APRE) stock, including its current price, analyst price targets, and historical performance. It details earnings, revenue, market capitalization, and various financial metrics such as EBITDA and volatility. The articl", "url": "https://www.tradingview.com/symbols/NASDAQ-APRE/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T20:09:39", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics, Inc. Actuals & Estimates (NASDAQ:APRE)", "summary": "This article provides an overview of Aprea Therapeutics, Inc. (NASDAQ: APRE) stock, including its current price, historical performance, and analyst forecasts. It also details financial data such as market capitalization, earnings per share, revenue, and net income, alongside inf", "url": "https://www.tradingview.com/symbols/NASDAQ-APRE/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T15:40:57", "published_display": "26 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Aprea Therapeutics Inc (APRE) has a current risk assessment score of 2.31, ranking 222 out of 389 in the Biotechnology & Medical Research industry. The company's beta of 1.46 indicates higher volatility compared to the S&P 500. The article details APRE's volatility, drawdown, and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-23T07:40:08", "published_display": "23 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Aprea Therapeutics, Inc. Insider Trading Activity", "summary": "Aprea Therapeutics director Gabriela Gruia received new equity compensation on June 16, 2026, including 3,135 restricted stock units and stock options for 12,555 shares at an exercise price of $0.7293. These grants will vest in full on June 16, 2027, contingent on her continued s", "url": "https://www.stocktitan.net/sec-filings/APRE/form-4-aprea-therapeutics-inc-insider-trading-activity-abcddc4c43cd.html", "source_name": "Stock Titan", "published_at": "2026-06-20T19:40:39", "published_display": "20 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Shareholders Approve Directors, Reverse Split Flexibility", "summary": "Aprea Therapeutics shareholders recently approved the election of three Class I directors and ratified the appointment of EisnerAmper LLP as their independent public accounting firm. They also authorized an amendment to the company's certificate of incorporation to allow for a re", "url": "https://www.theglobeandmail.com/investing/markets/stocks/APRE/pressreleases/2546234/aprea-shareholders-approve-directors-reverse-split-flexibility/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T04:39:12", "published_display": "19 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Institutional Confidence", "summary": "The article analyzes the institutional confidence score for Aprea Therapeutics Inc (APRE), which currently stands at 3.00, placing it 193 out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 46.24% quarter-over-qu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T15:40:43", "published_display": "18 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Aprea Therapeutics Inc (APRE), noting its current valuation score is 8.36, ranking 144th out of 388 in the Biotechnology & Medical Research industry. It highlights the company's negative P/E ratio and mentions that relevant data for P", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T09:38:57", "published_display": "18 Jun 2026 09:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Aprea Therapeutics Inc (APRE), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests the stock is currently in a range-boun", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/technical", "source_name": "TradingKey", "published_at": "2026-06-18T05:38:57", "published_display": "18 Jun 2026 05:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Shareholders Approve Reverse Stock Split and Key Proposals at 2026 Annual Meeting", "summary": "Aprea Therapeutics shareholders have approved a reverse stock split authorization, allowing the Board of Directors to enact a split ratio between 1-for-3 and 1-for-8. This decision, along with the election of three Class I directors and other key proposals, was made during the 20", "url": "https://www.minichart.com.sg/2026/06/18/aprea-therapeutics-shareholders-approve-reverse-stock-split-and-key-proposals-at-2026-annual-meeting/", "source_name": "Minichart", "published_at": "2026-06-18T04:38:57", "published_display": "18 Jun 2026 04:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Aprea Therapeutics Inc (APRE) has an earnings forecast score of 9.00, placing it 14th in the Biotechnology & Medical Research industry. Analysts have an average price target of $10.50 for APRE, with a strong buy rating based on four analyses. The company's expected revenue for th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:38:57", "published_display": "18 Jun 2026 02:38", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics shareholders approve director elections and reverse stock split", "summary": "Aprea Therapeutics shareholders have approved the election of three Class I directors and ratified EisnerAmper LLP as their independent registered accounting firm. Additionally, shareholders approved a reverse stock split at a ratio between one-for-three and one-for-eight, along ", "url": "https://ng.investing.com/news/sec-filings/aprea-therapeutics-shareholders-approve-director-elections-and-reverse-stock-split-93CH-2564193", "source_name": "Investing.com Nigeria", "published_at": "2026-06-18T00:08:00", "published_display": "18 Jun 2026 00:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on Aprea Therapeutics Inc (APRE) and its revenue breakdown. However, it explicitly states that relevant data for business segments and regional revenue and profit contribution have not yet been disclosed by the company. The page provides gener", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:10:11", "published_display": "17 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Aprea Therapeutics Inc (APRE), listing major individual and institutional holders along with their proportional ownership. It provides a breakdown of shareholder types such as individual investors, private equity, and hedge funds,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T17:10:11", "published_display": "17 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APRE: All agenda items, including director elections and reverse stock split, were approved", "summary": "Aprea Therapeutics (APRE) stockholders approved all agenda items during their 2026 Annual General Meeting. These items included director elections, auditor ratification, a reverse stock split, and executive compensation. Final voting results will be disclosed in a Form 8-K.", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3597927:0-apre-all-agenda-items-including-director-elections-and-reverse-stock-split-were-approved/", "source_name": "TradingView", "published_at": "2026-06-16T14:40:25", "published_display": "16 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics (APRE) AGM 2026 Summary", "summary": "Aprea Therapeutics (APRE) held its 2026 Annual General Meeting virtually on June 16, 2026. The agenda included elections for three directors, auditor ratification, authorization for a reverse stock split, executive compensation approval, and determination of say-on-pay frequency.", "url": "https://quartr.com/events/aprea-therapeutics-inc-apre-agm-2026_FPo5jRdL", "source_name": "Quartr", "published_at": "2026-06-16T14:40:24", "published_display": "16 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Aprea Therapeutics(APRE.US) With Buy Rating, Announces Target Price $5", "summary": "Oppenheimer has initiated coverage on Aprea Therapeutics (APRE.US) with a Buy rating. The firm has also set a target price of $5 for the stock. This news suggests a positive outlook from Oppenheimer regarding Aprea Therapeutics' future performance.", "url": "https://www.moomoo.com/news/post/71539587/oppenheimer-initiates-aprea-therapeutics-apreus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-06-15T15:40:43", "published_display": "15 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APRE - Aprea Therapeutics Inc Stock Price and Quote", "summary": "This page provides a detailed financial overview and news updates for Aprea Therapeutics Inc (APRE). It includes current stock price, financial metrics, analyst ratings, insider transactions, and a timeline of corporate announcements and clinical trial updates, particularly conce", "url": "https://finviz.com/stock?t=APRE", "source_name": "Finviz", "published_at": "2026-06-03T22:10:31", "published_display": "03 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $1.2", "summary": "H.C. Wainwright has reiterated its Buy rating for Aprea Therapeutics (APRE.US) and maintained its target price at $1.2. This indicates a continued positive outlook from the analytical firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/70875569/hc-wainwright-maintains-aprea-therapeutics-apreus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-01T21:10:50", "published_display": "01 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea's WEE1 Drug Shows Early Promise in Hard-to-Treat Cancers", "summary": "Aprea Therapeutics has announced promising early data from a Phase 1 trial of its novel WEE1 inhibitor, APR-1051, for advanced solid tumors. The drug showed anti-tumor activity, with partial tumor shrinkage in endometrial cancer patients and disease stabilization in others, along", "url": "https://briefglance.com/articles/apreas-wee1-drug-shows-early-promise-in-hard-to-treat-cancers", "source_name": "BriefGlance", "published_at": "2026-06-01T13:39:48", "published_display": "01 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors", "summary": "Aprea Therapeutics presented updated Phase 1 data for its WEE1 inhibitor, APR-1051, at ASCO 2026, showing early monotherapy activity and manageable tolerability in advanced solid tumors. The study, ACESOT-1051, reported partial responses and stable disease in heavily pretreated p", "url": "https://www.manilatimes.net/2026/06/01/tmt-newswire/globenewswire/aprea-therapeutics-presents-updated-phase-1-data-on-wee1-inhibitor-apr-1051-at-asco-2026-demonstrating-early-monotherapy-activity-and-manageable-tolerability-in-advanced-solid-tumors/2355776/amp", "source_name": "The Manila Times", "published_at": "2026-06-01T12:39:48", "published_display": "01 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer trial drug APR-1051 posts partial responses at ASCO 2026", "summary": "Aprea Therapeutics presented updated Phase 1 data for its WEE1 inhibitor, APR-1051, at ASCO 2026, showing early monotherapy activity and manageable tolerability in advanced solid tumors. The ACESOT-1051 study reported partial responses in two endometrial cancer patients and stabl", "url": "https://www.stocktitan.net/news/APRE/aprea-therapeutics-presents-updated-phase-1-data-on-wee1-inhibitor-5ycydujtqs2b.html", "source_name": "Stock Titan", "published_at": "2026-06-01T12:10:34", "published_display": "01 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics (APRE) Gains 2.78% as Shares Approach Key Resistance at $0.99 - Day Trade Opportunities", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQc1BsVU5hdnNQaFVKR3BxUUpmZmpkNUJQTXhpaHJ0ckp0VlV5czJVbUNVTTFlY0xuaGphdUYxRXNSS0EwRnpuVVNlcHZXdl84OWRFbG9aZlduMXltYVNlbDBvaU1sbFRVbWVUeGU3ZTZTcldWaDZKVF9raUh2c2wyTEJxdjhSQncxQWZBYVFheHAxeHZRcU5uQkJzMmJZUExLNzFsX3ZHNkJ2aWVpNFlKekpmQUw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics (APRE) upgraded to buy: Here's what you should know", "summary": "This article announces that Aprea Therapeutics (APRE) has received an upgraded \"buy\" rating. It suggests that investors should be aware of this development.", "url": "https://www.msn.com/en-us/money/topstocks/aprea-therapeutics-apre-upgraded-to-buy-heres-what-you-should-know/ar-AA23KRrF?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-23T14:09:34", "published_display": "23 May 2026 14:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing", "summary": "Aprea Therapeutics has filed a notice for the resale of up to 5.5 million shares by its selling stockholders. This information comes from a recent SEC filing. The company's stock symbol is APRE.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN41S1FK:0-aprea-therapeutics-files-for-resale-of-up-to-5-5-million-shares-by-selling-stockholders-sec-filing/", "source_name": "TradingView", "published_at": "2026-05-16T01:08:38", "published_display": "16 May 2026 01:08", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vestal Point reports 9.9% stake in Aprea Therapeutics (NASDAQ: APRE)", "summary": "Vestal Point Capital and Ryan Wilder have disclosed a 9.9% beneficial ownership stake in Aprea Therapeutics (NASDAQ: APRE) via a Schedule 13G filing. This stake, totaling 22,654,832 shares, predominantly includes shares issuable upon the exercise of warrants, some of which are su", "url": "https://www.stocktitan.net/sec-filings/APRE/schedule-13g-aprea-therapeutics-inc-passive-investment-disclosure-5-385d16d8ceda.html", "source_name": "Stock Titan", "published_at": "2026-05-16T00:08:38", "published_display": "16 May 2026 00:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[424B7] Aprea Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(7)", "summary": "Aprea Therapeutics, Inc. has filed a prospectus supplement (424B7) to register 5,503,556 shares of Common Stock for resale by selling stockholders, updating a previous prospectus from December 29, 2025. The filing details the composition of these shares, including those issued in", "url": "https://www.stocktitan.net/sec-filings/APRE/424b7-aprea-therapeutics-inc-prospectus-filed-pursuant-to-rule-424-b--6c69ea8c9fac.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:08:38", "published_display": "15 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Greater Philadelphia-based Aprea Therapeutics Raises $30M to Extend Runway and Reposition Its Precision Oncology Bet", "summary": "Aprea Therapeutics, based in Greater Philadelphia, has secured a $30 million private placement to advance its new lead program, APR-1051, a WEE1 kinase inhibitor for solid tumors. This funding aims to extend the company's cash runway into Q1 2028, allowing it to continue early cl", "url": "https://biobuzz.io/news/greater-philadelphia-based-aprea-therapeutics-raises-30m-to-extend-runway-and-reposition-its-precision-oncology-bet/", "source_name": "BioBuzz", "published_at": "2026-05-14T13:40:15", "published_display": "14 May 2026 13:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating", "summary": "Wedbush has revised its price target for Aprea Therapeutics to $6, down from the previous target of $7. Despite this reduction, the firm has decided to maintain its Outperform rating on the company's stock. This adjustment reflects a moderated outlook while still indicating confi", "url": "https://www.moomoo.com/news/post/70004033/wedbush-adjusts-price-target-on-aprea-therapeutics-to-6-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-14T10:39:02", "published_display": "14 May 2026 10:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update", "summary": "", "url": "https://finance.yahoo.com/news/aprea-therapeutics-reports-first-quarter-103000944.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T10:30:00+00:00", "published_display": "13 May 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQaEZXU2VsbDRkLW5KcGgyQ2xsbjdpT0JRM3YyUWljM243OWc1NTRXbnhKWWIydUFBOUFnOTRmSzNXSkUzRVJGbEU0bjJIQ1o3aGFZVE5KMlJZbEROR0tyX3lha2FnVjhjczhSVUp0R1gxeWh1RTRMRzZGWHBzalRoTUhsdmU1MUUxUGQ1VVN0VWw3aTcwdWZoM0hORUdBLWo5ME9xeWRXZWlsVU9KQ3c5c1RiMHRLU2FhYzNlUjhxSzI5LWhiaEpobk1wNDZubHU3?oc=5", "source_name": "ChartMill", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here Are Thursday\u2019s Top Wall Street Analyst Research Calls: Alcoa, Chiron Real Estate, Clear Secure, Fortinet, Fresh Pet, Kennametal, Oracle, PayPal, United Therapeutics, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwJBVV95cUxQb1g3azNZYWZ6ejJFeFp6RWVSTVRERi0tdWlVd0JRUjR0MGJTV05kenFOeW5LY1JidGY0d3dmakZtMGY5M0FicTZ4ZlRPdnFaSl81czB0NDNRTE5FZTVTMnhyS0FjTmNUM29hZmJGWUVrbTlrNGttNkRpZkpYb2RKaVBwVWh1NWVnbmNMNTRBa2d3LTF4NkRmNDUxNFI2cC1aTXViYV91ampWdHVrbUtZcDFVcXhlVTdNS1NWdG8zY2l6MEpUb0w3X0VTYXpjdmVYeWNZU0NpY1BGbFlVR0ZwYzE4d3UyaEtRVy1fZGVWeTZnUDZ3T0tXZ2JKem5uZ05nZlhVZ1EtR1dnWFNuWVlrVzRpR2xIb0VMRWlIUzVXMTdYb2tya3QzSV95Qm5wdFR4dkZkUFFpNA?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aprea-therapeutics-clinical-acesot-1051-141500403.html", "source_name": "GlobeNewswire", "published_at": "2026-04-21T14:15:00+00:00", "published_display": "21 Apr 2026 14:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics abstract accepted at ASCO meeting in May", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPNkVQQ2RHdW5PXzBaQmRIckQ4Z1NrMVRjWW5INnFJY0NHRXZhSWxFRzZWYzlUckhUQWVFamhkT3BqaTJJdE1VV25SWWExTkNqQWFXSlUyS19SZGVsT2tyVzlYZEhnYzl5Z1lwal94bFZodUMzYlROTHZZeEFrbDFjZmlvQ0VGRUJOTHNHQTdkRWtxNG9mcExWRlFZWTlLNFZoWThESGFfd2Z3d3pTZEx2Smo3NUxrWEU?oc=5", "source_name": "Investing.com", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aprea Therapeutics raises $30 million in private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOckhucTBYRUVRSnVZM0FKckQ1ZkdWWlgyenVyT0hfVUkyRWd4OFM4Q0xsNGo1dXVVYnIwbDhJTHVDNlNuQXpSWDhxQUdydmFIQTlrd3g3T0tuMThsVlh2WE84VXo4MHFMU1M0LVotMHhzY3pLbWFYNUgydlE0Ymp6WmNvUlRxTnRYTWtlV2Nicnp4b2k5VF8zRmJtODJ2aENQd1Bpa0x5M3kwZmU1VHVQVDdZWHc?oc=5", "source_name": "Investing.com", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tempest Therapeutics Announces Up To $6 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPd0NOc2stYWQ2UjBzZnpfazgwcTdidl9IZmlFOXN0NGpXdzd3a2J1WGJvdm5aSDB4YkNud05iNUlPRW1VZWtLTFItcnlfM2c1b2hJODR2NmRibWtJaHB1bFFHd2RpblltWXFSTThLdW1XamdPWHMyVk5DTDI1MS1EMXczY1k5c21PbXVaYTRYLXAxQjU0V0J6VEFETXBPeGhTdUhUOU4tbHdSdGxSYVE?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPaC1jelFqT05RdDZZY1RIdHNUTVhHbnVYOFBqTVNvbWJfdW1aY3NGWWtUMU9vN2FMTjNBbHJXS3l5eXJRQmpVelZtalRrZFAtQjNwUDZTdFctZldhSGw0RThLTENIVXlkSXBSR0F1TGJtUTdheXJtQXNwUjdXeHA5NXlMb1J3Sy15SEZvMk1YaHE1R1dl?oc=5", "source_name": "Market source", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Shares Slide After Phase 1 Cancer Drug Results Disappoint", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxONlYxTy1LYXhfWVB1S3RBVU5pVVdwNUptbnBkSHppb211WG1DWkIwVVByMmtDTlN1X3lhSDJ6RDlQaVRWYXg4eTV6VTduZ1EtWlJqaTd1VnV0dzg4LUZWcnU1Sm9aYVVPTjJ2MEdIUnNGNzFUMHJfaFVQU1IxY3Fpc1VUclNxNVF4Wm53QjktM19GRlJWOHRyZThWX2stNFpIUFBzZUdxdnZMZw?oc=5", "source_name": "StockInvest.us", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQbi11bGdkQVpFWGZ4Y0xYSUcxYVVnUDg0RS1nRmFSaHo4UVNRdGJLcWhRN01HSXFSODZZVzJJU19lZlRkZ0V6NUVuREhDTmNlaHlCQmxxU2FwV3VIcktUVHJkRHFEa3h5NW91RTc3NXg2NENWYl9EYTA2eGxoMF9CYVFCNWdNODFIZldtcGEwdExRTHRLRzJZ?oc=5", "source_name": "Market source", "published_at": "2025-09-11T07:00:00+00:00", "published_display": "11 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics (VYNE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE80OFZ6a3VhQTNHQ013Rl9UbmoyVGQyWDdaVUxVQlQxbHNCcmZTcTlXMHNQVVVpVnJyclgzOTQybFkyUnBJbmNWUmU1dkg4VmVTREVn?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:41:49+00:00", "published_display": "25 Apr 2025 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for Aprea Therapeutics (APRE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBZNjBiZGlZYVhTQXdLbWFTQzN0WVJueU5KUDF1djZ2elE4Rno5c0NNRmRGb1NYcTNjbktkOUk2NklldlhRSTZ2NXBraHF5YnFObVRwN3hYby1oSWd6WGdoN09ZT0VyNEg2Ynp1Nkx2d2VGb1hvQmFabA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-08-29T13:52:31+00:00", "published_display": "29 Aug 2022 13:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Stock Price Forecast. Should You Buy APRE?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE52QUlaRFJzMVJjOGlJajZqYXZJM0ItbkJjcC1lZDBRZThGdkdEYkh1MWxYSHBtTE1rY2M1c3BXdzRuaTc4eEdGVQ?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-04T21:00:37+00:00", "published_display": "04 Dec 2020 21:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics (APRE) Stock Price, News & Analysis $APRE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5VU2ZxbU9pSllQeDJIc1Z5Z2dGLUk4LVplVXVyQjMzM0VyTE1PRmJuVFdDNTZ5NklfaXhaVll0UXdVcS1rd0JWVnBwOGhLWXZPRXcwY2FNZl9RZw?oc=5", "source_name": "MarketBeat", "published_at": "2019-10-09T15:24:40+00:00", "published_display": "09 Oct 2019 15:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APRE Stock Price and Chart \u2014 NASDAQ:APRE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBLY3pRV0F1REdwcElWaHJsdjhteDBWWlJmRE5uZmFaUVkxTzZsQXZzTmNPYkNubzhGLVhxRWRFLTlCekhNNUpxV24zZ3VxSUpOWHB3WUtHTnBCWGdG?oc=5", "source_name": "TradingView", "published_at": "2019-10-07T17:44:00+00:00", "published_display": "07 Oct 2019 17:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Aprea Therapeutics (APRE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9MY3VBUWxEMm1qWGlCc3lOUGNLVjhXVEo5aEM1NDZiRVBtSU9PLXFDRk9sTm1XbTlPb2tMWFRBZE5fbXNwQW94NEtLWGszZ2xrRm5zdjFGT2Z6aHBoN3g1N0JzSVRDRmhmM2FVWQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2016-08-23T06:53:28+00:00", "published_display": "23 Aug 2016 06:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxQOWRyOXFBVDdjdUw1aVZSX2VSckJGR1Jac2hiWXVFS2loVk1qUXhuN2ZaQ2ZUYmh1ZVlqTzZ5eGJoRS1jVDF6Z3BHbnotN0otZjhKV05IbFNqMW5VXy1VMjEyQ2tGWUVETlNNbTFQMWZPUV9jRHFBNEIxZTUzalFrS2tCSHVrZmt1bzJ6Q2lGRVVZdEVjeTFBRFhLbUtOUUdGQ3lERFRvRWlwbkhRRkxqMm5odjM5R2Q2NGlFTzFhUVN6U2l5SVlkOHV6WGl4dHJsbUlrN25XU1VUdkFnSk02S3dBdHlvRGlaQ2Q4V2hoU056VXJ3ZXpBbDV6WmI?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T23:28:21+00:00", "published_display": "14 Jul 2026 23:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Aprea Therapeutics, Inc. \u2013 NASDAQ:APRE", "summary": "This article provides financial information for Aprea Therapeutics, Inc. (NASDAQ: APRE), specifically detailing its Enterprise Value to EBITDA forward. It lists various data providers for market and reference data, along with several copyright notices. The content appears to be a", "url": "https://www.tradingview.com/symbols/NASDAQ-APRE/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T11:39:18", "published_display": "06 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APRE - Aprea Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial snapshot of Aprea Therapeutics Inc (APRE), including its latest stock performance, key financial metrics, volatility, and various fundamental and technical indicators. It covers share statistics, profitability ratios, earnings per share,", "url": "https://finviz.com/stock?t=APRE&p=w&b=1&r=y2&ty=ocv&e=2026-04-20", "source_name": "Finviz", "published_at": "2026-07-04T10:41:07", "published_display": "04 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APRE Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Aprea Therapeutics, Inc. (APRE) stock, including its current price, analyst price targets, and historical performance. It details earnings, revenue, market capitalization, and various financial metrics such as EBITDA and volatility. The articl", "url": "https://www.tradingview.com/symbols/NASDAQ-APRE/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T20:09:39", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics, Inc. Actuals & Estimates (NASDAQ:APRE)", "summary": "This article provides an overview of Aprea Therapeutics, Inc. (NASDAQ: APRE) stock, including its current price, historical performance, and analyst forecasts. It also details financial data such as market capitalization, earnings per share, revenue, and net income, alongside inf", "url": "https://www.tradingview.com/symbols/NASDAQ-APRE/forecast-actuals-and-estimates/?category=cash_flow", "source_name": "TradingView", "published_at": "2026-06-26T15:40:57", "published_display": "26 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Aprea Therapeutics Inc (APRE) has a current risk assessment score of 2.31, ranking 222 out of 389 in the Biotechnology & Medical Research industry. The company's beta of 1.46 indicates higher volatility compared to the S&P 500. The article details APRE's volatility, drawdown, and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-23T07:40:08", "published_display": "23 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Aprea Therapeutics, Inc. Insider Trading Activity", "summary": "Aprea Therapeutics director Gabriela Gruia received new equity compensation on June 16, 2026, including 3,135 restricted stock units and stock options for 12,555 shares at an exercise price of $0.7293. These grants will vest in full on June 16, 2027, contingent on her continued s", "url": "https://www.stocktitan.net/sec-filings/APRE/form-4-aprea-therapeutics-inc-insider-trading-activity-abcddc4c43cd.html", "source_name": "Stock Titan", "published_at": "2026-06-20T19:40:39", "published_display": "20 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Shareholders Approve Directors, Reverse Split Flexibility", "summary": "Aprea Therapeutics shareholders recently approved the election of three Class I directors and ratified the appointment of EisnerAmper LLP as their independent public accounting firm. They also authorized an amendment to the company's certificate of incorporation to allow for a re", "url": "https://www.theglobeandmail.com/investing/markets/stocks/APRE/pressreleases/2546234/aprea-shareholders-approve-directors-reverse-split-flexibility/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T04:39:12", "published_display": "19 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Institutional Confidence", "summary": "The article analyzes the institutional confidence score for Aprea Therapeutics Inc (APRE), which currently stands at 3.00, placing it 193 out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has decreased by 46.24% quarter-over-qu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T15:40:43", "published_display": "18 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Aprea Therapeutics Inc (APRE), noting its current valuation score is 8.36, ranking 144th out of 388 in the Biotechnology & Medical Research industry. It highlights the company's negative P/E ratio and mentions that relevant data for P", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T09:38:57", "published_display": "18 Jun 2026 09:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Aprea Therapeutics Inc (APRE), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests the stock is currently in a range-boun", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/technical", "source_name": "TradingKey", "published_at": "2026-06-18T05:38:57", "published_display": "18 Jun 2026 05:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Shareholders Approve Reverse Stock Split and Key Proposals at 2026 Annual Meeting", "summary": "Aprea Therapeutics shareholders have approved a reverse stock split authorization, allowing the Board of Directors to enact a split ratio between 1-for-3 and 1-for-8. This decision, along with the election of three Class I directors and other key proposals, was made during the 20", "url": "https://www.minichart.com.sg/2026/06/18/aprea-therapeutics-shareholders-approve-reverse-stock-split-and-key-proposals-at-2026-annual-meeting/", "source_name": "Minichart", "published_at": "2026-06-18T04:38:57", "published_display": "18 Jun 2026 04:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Aprea Therapeutics Inc (APRE) has an earnings forecast score of 9.00, placing it 14th in the Biotechnology & Medical Research industry. Analysts have an average price target of $10.50 for APRE, with a strong buy rating based on four analyses. The company's expected revenue for th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:38:57", "published_display": "18 Jun 2026 02:38", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics shareholders approve director elections and reverse stock split", "summary": "Aprea Therapeutics shareholders have approved the election of three Class I directors and ratified EisnerAmper LLP as their independent registered accounting firm. Additionally, shareholders approved a reverse stock split at a ratio between one-for-three and one-for-eight, along ", "url": "https://ng.investing.com/news/sec-filings/aprea-therapeutics-shareholders-approve-director-elections-and-reverse-stock-split-93CH-2564193", "source_name": "Investing.com Nigeria", "published_at": "2026-06-18T00:08:00", "published_display": "18 Jun 2026 00:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on Aprea Therapeutics Inc (APRE) and its revenue breakdown. However, it explicitly states that relevant data for business segments and regional revenue and profit contribution have not yet been disclosed by the company. The page provides gener", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:10:11", "published_display": "17 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Inc (APRE) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Aprea Therapeutics Inc (APRE), listing major individual and institutional holders along with their proportional ownership. It provides a breakdown of shareholder types such as individual investors, private equity, and hedge funds,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-apre/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T17:10:11", "published_display": "17 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APRE: All agenda items, including director elections and reverse stock split, were approved", "summary": "Aprea Therapeutics (APRE) stockholders approved all agenda items during their 2026 Annual General Meeting. These items included director elections, auditor ratification, a reverse stock split, and executive compensation. Final voting results will be disclosed in a Form 8-K.", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3597927:0-apre-all-agenda-items-including-director-elections-and-reverse-stock-split-were-approved/", "source_name": "TradingView", "published_at": "2026-06-16T14:40:25", "published_display": "16 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics (APRE) AGM 2026 Summary", "summary": "Aprea Therapeutics (APRE) held its 2026 Annual General Meeting virtually on June 16, 2026. The agenda included elections for three directors, auditor ratification, authorization for a reverse stock split, executive compensation approval, and determination of say-on-pay frequency.", "url": "https://quartr.com/events/aprea-therapeutics-inc-apre-agm-2026_FPo5jRdL", "source_name": "Quartr", "published_at": "2026-06-16T14:40:24", "published_display": "16 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oppenheimer Initiates Aprea Therapeutics(APRE.US) With Buy Rating, Announces Target Price $5", "summary": "Oppenheimer has initiated coverage on Aprea Therapeutics (APRE.US) with a Buy rating. The firm has also set a target price of $5 for the stock. This news suggests a positive outlook from Oppenheimer regarding Aprea Therapeutics' future performance.", "url": "https://www.moomoo.com/news/post/71539587/oppenheimer-initiates-aprea-therapeutics-apreus-with-buy-rating-announces-target", "source_name": "Moomoo", "published_at": "2026-06-15T15:40:43", "published_display": "15 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APRE - Aprea Therapeutics Inc Stock Price and Quote", "summary": "This page provides a detailed financial overview and news updates for Aprea Therapeutics Inc (APRE). It includes current stock price, financial metrics, analyst ratings, insider transactions, and a timeline of corporate announcements and clinical trial updates, particularly conce", "url": "https://finviz.com/stock?t=APRE", "source_name": "Finviz", "published_at": "2026-06-03T22:10:31", "published_display": "03 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $1.2", "summary": "H.C. Wainwright has reiterated its Buy rating for Aprea Therapeutics (APRE.US) and maintained its target price at $1.2. This indicates a continued positive outlook from the analytical firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/70875569/hc-wainwright-maintains-aprea-therapeutics-apreus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-01T21:10:50", "published_display": "01 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea's WEE1 Drug Shows Early Promise in Hard-to-Treat Cancers", "summary": "Aprea Therapeutics has announced promising early data from a Phase 1 trial of its novel WEE1 inhibitor, APR-1051, for advanced solid tumors. The drug showed anti-tumor activity, with partial tumor shrinkage in endometrial cancer patients and disease stabilization in others, along", "url": "https://briefglance.com/articles/apreas-wee1-drug-shows-early-promise-in-hard-to-treat-cancers", "source_name": "BriefGlance", "published_at": "2026-06-01T13:39:48", "published_display": "01 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors", "summary": "Aprea Therapeutics presented updated Phase 1 data for its WEE1 inhibitor, APR-1051, at ASCO 2026, showing early monotherapy activity and manageable tolerability in advanced solid tumors. The study, ACESOT-1051, reported partial responses and stable disease in heavily pretreated p", "url": "https://www.manilatimes.net/2026/06/01/tmt-newswire/globenewswire/aprea-therapeutics-presents-updated-phase-1-data-on-wee1-inhibitor-apr-1051-at-asco-2026-demonstrating-early-monotherapy-activity-and-manageable-tolerability-in-advanced-solid-tumors/2355776/amp", "source_name": "The Manila Times", "published_at": "2026-06-01T12:39:48", "published_display": "01 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer trial drug APR-1051 posts partial responses at ASCO 2026", "summary": "Aprea Therapeutics presented updated Phase 1 data for its WEE1 inhibitor, APR-1051, at ASCO 2026, showing early monotherapy activity and manageable tolerability in advanced solid tumors. The ACESOT-1051 study reported partial responses in two endometrial cancer patients and stabl", "url": "https://www.stocktitan.net/news/APRE/aprea-therapeutics-presents-updated-phase-1-data-on-wee1-inhibitor-5ycydujtqs2b.html", "source_name": "Stock Titan", "published_at": "2026-06-01T12:10:34", "published_display": "01 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics (APRE) Gains 2.78% as Shares Approach Key Resistance at $0.99 - Day Trade Opportunities", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQc1BsVU5hdnNQaFVKR3BxUUpmZmpkNUJQTXhpaHJ0ckp0VlV5czJVbUNVTTFlY0xuaGphdUYxRXNSS0EwRnpuVVNlcHZXdl84OWRFbG9aZlduMXltYVNlbDBvaU1sbFRVbWVUeGU3ZTZTcldWaDZKVF9raUh2c2wyTEJxdjhSQncxQWZBYVFheHAxeHZRcU5uQkJzMmJZUExLNzFsX3ZHNkJ2aWVpNFlKekpmQUw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics (APRE) upgraded to buy: Here's what you should know", "summary": "This article announces that Aprea Therapeutics (APRE) has received an upgraded \"buy\" rating. It suggests that investors should be aware of this development.", "url": "https://www.msn.com/en-us/money/topstocks/aprea-therapeutics-apre-upgraded-to-buy-heres-what-you-should-know/ar-AA23KRrF?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-23T14:09:34", "published_display": "23 May 2026 14:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing", "summary": "Aprea Therapeutics has filed a notice for the resale of up to 5.5 million shares by its selling stockholders. This information comes from a recent SEC filing. The company's stock symbol is APRE.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN41S1FK:0-aprea-therapeutics-files-for-resale-of-up-to-5-5-million-shares-by-selling-stockholders-sec-filing/", "source_name": "TradingView", "published_at": "2026-05-16T01:08:38", "published_display": "16 May 2026 01:08", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vestal Point reports 9.9% stake in Aprea Therapeutics (NASDAQ: APRE)", "summary": "Vestal Point Capital and Ryan Wilder have disclosed a 9.9% beneficial ownership stake in Aprea Therapeutics (NASDAQ: APRE) via a Schedule 13G filing. This stake, totaling 22,654,832 shares, predominantly includes shares issuable upon the exercise of warrants, some of which are su", "url": "https://www.stocktitan.net/sec-filings/APRE/schedule-13g-aprea-therapeutics-inc-passive-investment-disclosure-5-385d16d8ceda.html", "source_name": "Stock Titan", "published_at": "2026-05-16T00:08:38", "published_display": "16 May 2026 00:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[424B7] Aprea Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(7)", "summary": "Aprea Therapeutics, Inc. has filed a prospectus supplement (424B7) to register 5,503,556 shares of Common Stock for resale by selling stockholders, updating a previous prospectus from December 29, 2025. The filing details the composition of these shares, including those issued in", "url": "https://www.stocktitan.net/sec-filings/APRE/424b7-aprea-therapeutics-inc-prospectus-filed-pursuant-to-rule-424-b--6c69ea8c9fac.html", "source_name": "Stock Titan", "published_at": "2026-05-15T20:08:38", "published_display": "15 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Greater Philadelphia-based Aprea Therapeutics Raises $30M to Extend Runway and Reposition Its Precision Oncology Bet", "summary": "Aprea Therapeutics, based in Greater Philadelphia, has secured a $30 million private placement to advance its new lead program, APR-1051, a WEE1 kinase inhibitor for solid tumors. This funding aims to extend the company's cash runway into Q1 2028, allowing it to continue early cl", "url": "https://biobuzz.io/news/greater-philadelphia-based-aprea-therapeutics-raises-30m-to-extend-runway-and-reposition-its-precision-oncology-bet/", "source_name": "BioBuzz", "published_at": "2026-05-14T13:40:15", "published_display": "14 May 2026 13:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating", "summary": "Wedbush has revised its price target for Aprea Therapeutics to $6, down from the previous target of $7. Despite this reduction, the firm has decided to maintain its Outperform rating on the company's stock. This adjustment reflects a moderated outlook while still indicating confi", "url": "https://www.moomoo.com/news/post/70004033/wedbush-adjusts-price-target-on-aprea-therapeutics-to-6-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-14T10:39:02", "published_display": "14 May 2026 10:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update", "summary": "", "url": "https://finance.yahoo.com/news/aprea-therapeutics-reports-first-quarter-103000944.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T10:30:00+00:00", "published_display": "13 May 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQaEZXU2VsbDRkLW5KcGgyQ2xsbjdpT0JRM3YyUWljM243OWc1NTRXbnhKWWIydUFBOUFnOTRmSzNXSkUzRVJGbEU0bjJIQ1o3aGFZVE5KMlJZbEROR0tyX3lha2FnVjhjczhSVUp0R1gxeWh1RTRMRzZGWHBzalRoTUhsdmU1MUUxUGQ1VVN0VWw3aTcwdWZoM0hORUdBLWo5ME9xeWRXZWlsVU9KQ3c5c1RiMHRLU2FhYzNlUjhxSzI5LWhiaEpobk1wNDZubHU3?oc=5", "source_name": "ChartMill", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here Are Thursday\u2019s Top Wall Street Analyst Research Calls: Alcoa, Chiron Real Estate, Clear Secure, Fortinet, Fresh Pet, Kennametal, Oracle, PayPal, United Therapeutics, and More", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwJBVV95cUxQb1g3azNZYWZ6ejJFeFp6RWVSTVRERi0tdWlVd0JRUjR0MGJTV05kenFOeW5LY1JidGY0d3dmakZtMGY5M0FicTZ4ZlRPdnFaSl81czB0NDNRTE5FZTVTMnhyS0FjTmNUM29hZmJGWUVrbTlrNGttNkRpZkpYb2RKaVBwVWh1NWVnbmNMNTRBa2d3LTF4NkRmNDUxNFI2cC1aTXViYV91ampWdHVrbUtZcDFVcXhlVTdNS1NWdG8zY2l6MEpUb0w3X0VTYXpjdmVYeWNZU0NpY1BGbFlVR0ZwYzE4d3UyaEtRVy1fZGVWeTZnUDZ3T0tXZ2JKem5uZ05nZlhVZ1EtR1dnWFNuWVlrVzRpR2xIb0VMRWlIUzVXMTdYb2tya3QzSV95Qm5wdFR4dkZkUFFpNA?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aprea-therapeutics-clinical-acesot-1051-141500403.html", "source_name": "GlobeNewswire", "published_at": "2026-04-21T14:15:00+00:00", "published_display": "21 Apr 2026 14:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics abstract accepted at ASCO meeting in May", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPNkVQQ2RHdW5PXzBaQmRIckQ4Z1NrMVRjWW5INnFJY0NHRXZhSWxFRzZWYzlUckhUQWVFamhkT3BqaTJJdE1VV25SWWExTkNqQWFXSlUyS19SZGVsT2tyVzlYZEhnYzl5Z1lwal94bFZodUMzYlROTHZZeEFrbDFjZmlvQ0VGRUJOTHNHQTdkRWtxNG9mcExWRlFZWTlLNFZoWThESGFfd2Z3d3pTZEx2Smo3NUxrWEU?oc=5", "source_name": "Investing.com", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics raises $30 million in private placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOckhucTBYRUVRSnVZM0FKckQ1ZkdWWlgyenVyT0hfVUkyRWd4OFM4Q0xsNGo1dXVVYnIwbDhJTHVDNlNuQXpSWDhxQUdydmFIQTlrd3g3T0tuMThsVlh2WE84VXo4MHFMU1M0LVotMHhzY3pLbWFYNUgydlE0Ymp6WmNvUlRxTnRYTWtlV2Nicnp4b2k5VF8zRmJtODJ2aENQd1Bpa0x5M3kwZmU1VHVQVDdZWHc?oc=5", "source_name": "Investing.com", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tempest Therapeutics Announces Up To $6 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPd0NOc2stYWQ2UjBzZnpfazgwcTdidl9IZmlFOXN0NGpXdzd3a2J1WGJvdm5aSDB4YkNud05iNUlPRW1VZWtLTFItcnlfM2c1b2hJODR2NmRibWtJaHB1bFFHd2RpblltWXFSTThLdW1XamdPWHMyVk5DTDI1MS1EMXczY1k5c21PbXVaYTRYLXAxQjU0V0J6VEFETXBPeGhTdUhUOU4tbHdSdGxSYVE?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPaC1jelFqT05RdDZZY1RIdHNUTVhHbnVYOFBqTVNvbWJfdW1aY3NGWWtUMU9vN2FMTjNBbHJXS3l5eXJRQmpVelZtalRrZFAtQjNwUDZTdFctZldhSGw0RThLTENIVXlkSXBSR0F1TGJtUTdheXJtQXNwUjdXeHA5NXlMb1J3Sy15SEZvMk1YaHE1R1dl?oc=5", "source_name": "Market source", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Shares Slide After Phase 1 Cancer Drug Results Disappoint", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxONlYxTy1LYXhfWVB1S3RBVU5pVVdwNUptbnBkSHppb211WG1DWkIwVVByMmtDTlN1X3lhSDJ6RDlQaVRWYXg4eTV6VTduZ1EtWlJqaTd1VnV0dzg4LUZWcnU1Sm9aYVVPTjJ2MEdIUnNGNzFUMHJfaFVQU1IxY3Fpc1VUclNxNVF4Wm53QjktM19GRlJWOHRyZThWX2stNFpIUFBzZUdxdnZMZw?oc=5", "source_name": "StockInvest.us", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQbi11bGdkQVpFWGZ4Y0xYSUcxYVVnUDg0RS1nRmFSaHo4UVNRdGJLcWhRN01HSXFSODZZVzJJU19lZlRkZ0V6NUVuREhDTmNlaHlCQmxxU2FwV3VIcktUVHJkRHFEa3h5NW91RTc3NXg2NENWYl9EYTA2eGxoMF9CYVFCNWdNODFIZldtcGEwdExRTHRLRzJZ?oc=5", "source_name": "Market source", "published_at": "2025-09-11T07:00:00+00:00", "published_display": "11 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vyne Therapeutics (VYNE) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE80OFZ6a3VhQTNHQ013Rl9UbmoyVGQyWDdaVUxVQlQxbHNCcmZTcTlXMHNQVVVpVnJyclgzOTQybFkyUnBJbmNWUmU1dkg4VmVTREVn?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:41:49+00:00", "published_display": "25 Apr 2025 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What is the current Price Target and Forecast for Aprea Therapeutics (APRE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBZNjBiZGlZYVhTQXdLbWFTQzN0WVJueU5KUDF1djZ2elE4Rno5c0NNRmRGb1NYcTNjbktkOUk2NklldlhRSTZ2NXBraHF5YnFObVRwN3hYby1oSWd6WGdoN09ZT0VyNEg2Ynp1Nkx2d2VGb1hvQmFabA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2022-08-29T13:52:31+00:00", "published_display": "29 Aug 2022 13:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics Stock Price Forecast. Should You Buy APRE?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE52QUlaRFJzMVJjOGlJajZqYXZJM0ItbkJjcC1lZDBRZThGdkdEYkh1MWxYSHBtTE1rY2M1c3BXdzRuaTc4eEdGVQ?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-04T21:00:37+00:00", "published_display": "04 Dec 2020 21:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aprea Therapeutics (APRE) Stock Price, News & Analysis $APRE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5VU2ZxbU9pSllQeDJIc1Z5Z2dGLUk4LVplVXVyQjMzM0VyTE1PRmJuVFdDNTZ5NklfaXhaVll0UXdVcS1rd0JWVnBwOGhLWXZPRXcwY2FNZl9RZw?oc=5", "source_name": "MarketBeat", "published_at": "2019-10-09T15:24:40+00:00", "published_display": "09 Oct 2019 15:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "APRE Stock Price and Chart \u2014 NASDAQ:APRE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBLY3pRV0F1REdwcElWaHJsdjhteDBWWlJmRE5uZmFaUVkxTzZsQXZzTmNPYkNubzhGLVhxRWRFLTlCekhNNUpxV24zZ3VxSUpOWHB3WUtHTnBCWGdG?oc=5", "source_name": "TradingView", "published_at": "2019-10-07T17:44:00+00:00", "published_display": "07 Oct 2019 17:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Aprea Therapeutics (APRE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE9MY3VBUWxEMm1qWGlCc3lOUGNLVjhXVEo5aEM1NDZiRVBtSU9PLXFDRk9sTm1XbTlPb2tMWFRBZE5fbXNwQW94NEtLWGszZ2xrRm5zdjFGT2Z6aHBoN3g1N0JzSVRDRmhmM2FVWQ?oc=5", "source_name": "Zacks Investment Research", "published_at": "2016-08-23T06:53:28+00:00", "published_display": "23 Aug 2016 06:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 56, "sentiment_summary": {"positive": 15, "negative": 7, "neutral": 34, "score": 54, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 15.2, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 8.66, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 0.74, "latest_week": "2026-07-10", "one_week_move": 0.5, "four_week_move": 8.6, "twelve_week_move": -25.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.017041, "market_dynamics_buy_signal": false, "relative_strength": -42.491154, "fair_value_gap": -74.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 39.5637, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.5% over one week, +8.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 52, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingView", "count": 7}, {"label": "TradingKey", "count": 7}, {"label": "Stock Titan", "count": 5}, {"label": "Moomoo", "count": 3}, {"label": "Finviz", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "GlobeNewswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 6}, {"label": "Guidance", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.5% over one week, +8.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial"}], "updated_at": "2026-07-17T20:13:24.680827+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}